Sanofi receives orphan status from EMA for rilzabrutinib
Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK)…
Immunology
-
-
US eosinophilic oesophagitis market to reach $1.19bn by 2030
The eosinophilic oesophagitis (EoE) market in the US is forecast to grow from $202 million in 2020 to $1.19 billion…
-
BMS and Bain Capital forge $300m immunology spinoff
Following the pharmaceutical giant’s intentions to home in on its immunology portfolio, Bristol Myers Squibb (BMS) has teamed up with…
-
HS market forecast to reach $7.8bn across 7MM by 2034
The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)…
-
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
-
Kling Bio and Sanofi link for antibodies and epitopes discovery
Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes. The partnership…
-
Sanofi to acquire Vicebio’s share capital for $1.15bn upfront
Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine…
-
FDA approves GSK’s prefilled syringe presentation of Shingrix
The US Food and Drug Administration (FDA) has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled…
-
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in…
-
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for review to treat…
